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Fractional exhaled nitric oxide (FeNO) is a non invasive method for assessing the inflammatory status of children
with airway disease. Different ways to measure FeNO levels are currently available. The possibility of measuring
FeNO levels in an office setting even in young children, and the commercial availability of portable devices, support
the routine use of FeNO determination in the daily pediatric practice. Although many confounding factors may
affect its measurement, FeNO is now widely used in the management of children with asthma, and seems to
provide significantly higher diagnostic accuracy than lung function or bronchial challenge tests. The role of FeNO in
airway infection (e.g. viral bronchiolitis and common acquired pneumonia), in bronchiectasis, or in cases with
diffuse lung disease is less clear. This review focuses on the most recent advances and the current clinical
applications of FeNO measurement in pediatric lung disease.
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Bronchiectasis, Diffuse lung diseaseIntroduction
Nitric oxide (NO) is a biological mediator synthesized by
NO synthase (NOS), an enzyme that catalyzes the oxida-
tion of L-arginine to NO and L-citrulline. Constitutive
NOS isoenzymes include neuronal NOS (NOS1) and
endothelial NOS (NOS3), both of which are activated by
calcium ions to produce small amounts of NO [1]. Indu-
cible NOS (NOS2), that is induced by inflammatory and
infectious stimuli, produces large amounts of NO inde-
pendent of calcium ion influx [2]. NO was first described
as a vascular smooth muscle relaxant and was subse-
quently found to be present in the expired breath of ani-
mals and humans [1]. In the lungs, NO determines
smooth muscle relaxation, affects ciliary beat frequency,
mucus secretion and plasma exudation, and is involved
in neurotransmission, blood flow regulation, inflamma-
tion and cell-mediated immunity processes [3]. In the
upper respiratory tract NO levels are higher than in the
lower airways, with the maximal concentration in the* Correspondence: santamar@unina.it
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reproduction in any medium, provided the orparanasal sinuses, probably because of local increased
NOS activity and of poor ventilation [4].
During the last years the availability of NO analyzers
and the publication of official guidelines made the mea-
surement of fractional exhaled NO (FeNO) a useful tool
in the diagnosis of various pediatric airway disorders
[5-10]. This review summarizes the most recent advances
and the current clinical applications of FeNO measure-
ment in the pediatric clinical practice.How should FeNO be measured?
Several methods are used to measure FeNO in children,
and the choice depends on the subject’s age and coope-
ration. Online measurement allows FeNO testing with a
real-time display of NO breath profiles, which is available
in stationary devices only. Offline testing, instead, refers to
collection of exhaled air into suitable receptacles for
delayed analysis [5]. The single breath online measurement
is the gold standard in school-age children [5,11]. The sub-
ject is asked to inhale to near total lung capacity and to
exhale at a constant flow of 50 mL/s until a NO plateau of
at least 2 seconds can be identified. The offline method
with constant flow rate is the offline method of choice in
school-age children [5]. The child blows air through aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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vented by closing the velum by exhaling against at least 5
cm H2O oral pressure. NO concentrations in balloons can
be stable for several hours, and the measurement can take
place also at a distant site. Flow rate standardization
improves the reproducibility of the offline technique, with
results similar to the online constant flow rate methods
[11]. In subjects younger than 5 years, single-breath online
measurement is not well standardized since children cannot
adequately cooperate. In the age group from 2 to 5 years,
FeNO levels are measured online during spontaneous
breathing, with the exhalation flow adjusted to 50 mL/s by
changing the exhalation resistance [12]. The child breathes
quietly, slowly and regularly through a mouthpiece con-
nected to a two-way valve. NO-free air is continuously
flushed through the inlet of the valve. However, NO levels
measured during spontaneous breathing may not equate
with single-breath online measurements. In children
younger than 2 years, the tidal breathing method has been
used both online and offline, but it is not standardized [11].
Finally, the agreement between different devices
gave inconsistent results, with some studies showing
significant differences between analyzers [13], while
others showed a high degree of agreement between
different devices [14-16]. In particular, a recent study
demonstrated an acceptable degree of agreement
only between devices from the same manufacturer,
both stationary and portable [17].FeNO reference values in exhaled air
Several recent publications have reported reference values
for FeNO in children and adolescents [18-28] (Table 1).
There are important differences among these studies
regarding to the size of the examined population as well as
the range of statistical variables that have been included orTable 1 FeNO reference values in healthy children and adoles
Author [reference] N Subjects N
Dötsch 1996 [24] 37 Caucasian, 4-18 years
Baraldi 1999 [18] 159 Caucasian, 6–15 years
Silvestri 1999 [25] 22 Caucasian, 11-12 years
Franklin 1999 [26] 157 Caucasian, 7-13 years
Latzin 2002 [27] 107 Caucasian, 4-18 years
Jouaville 2003 [28] 96 Caucasian, 9-10 years
Buchvald 2005 [19] 405 Caucasian, Hispanic, Asian, Black, 4–17 years
Wong 2005 [21] 291 Chinese, 11-18 years
Caucasian, 11-18 years
Malmberg 2006 [22] 114 Caucasian, 7.2-15.7 years
r
Kovesi 2008 [20] 657 White, Black, Asian, 9.1-12.9 years
Yao 2012 [23] 693 Asiatic, 5-18 years
*Expressed as mean values.excluded, limiting their value. Several factors may affect
FeNO levels: measurement techniques, exhalation flow rate,
nasal NO contamination, NO analyzer used, race, age, sex,
atopy, anthropometric measures, smoking, and diet. While
some of these (height, age, smoke, atopy) are universally
accepted as crucial in increasing FeNO values [20,29], there
is uncertainty regarding the others [30-32].FeNO and bronchial asthma
FeNO in the diagnosis of bronchial asthma
Chronic airway inflammation is an important feature in
the development and progression of bronchial asthma
[10,33-36]. FeNO levels are increased in asthmatic
patients [37-39] as a result of induction of NOS2 by proin-
flammatory cytokines [3,40-43]. There is some degree of
correlation between elevated FeNO levels and increased
eosinophils in blood, bronchoalveolar lavage fluid [28],
bronchial biopsies [44], sputum [45], this indicating that
FeNO reflects eosinophilic inflammation [28,33,46,47].
However, asthma is probably not a single disease since at
least 3 adult phenotypes of airway inflammation have been
identified on the basis of predominant eosinophilic, neu-
trophilic, or pauci-granulocitic cellular pattern [48]. It is
therefore not surprising that the difference in FeNO levels
between symptomatic and asymptomatic children is rela-
tively small, and a large overlap in the distribution of
FeNO levels from subjects with and without asthma has
been reported [49-58] (Table 2). Another limitation is that
even though FeNO is increased in children with allergic
asthma [59-62], the obtained levels cannot discriminate
among schoolchildren with non-allergic asthma, or those
with allergy without asthma, or the healthy population
[63]. Moreover, levels of FeNO appear increased in asth-
matics with pollen allergy during the season also in the
absence of symptoms of lung function impairment [64].cents
ormal values* Analyzer
3.1 ppb CLD 700; Eco Physics, Dürnten, Switzerland
8.7 ppb CLD 700, Al-Med, Ecophysics, Durnten, Switzerland
4.0 ppb LR 2000, Logan System, Rochester, Kent, UK
7.4 ppb NOA 280, Seivers Instruments Inc., Boulder, CO
9.2 ppb LR 2000, Logan Research, Rochester, UK
13.3 ppb Sievers Instruments, Boulder, CO, USA, kit bag collection
9.7 ppb NIOX, Aerocrine AB, Stockholm, Sweden





NIOX, Aerocrine AB, Stockholm, Sweden
12.7 ppb CLD 88sp, Eco Medics AG; Durnten, Switzerland
13.7 ppb CLD 88sp, Eco Medics AG; Durnten, Switzerland
Table 2 Diagnostic accuracy of FeNO measurement in patients with asthma
Author [reference] Subjects Patients with asthma (%) FeNO cut-point Sensitivity (%) Specificity (%)
Malmberg 2003 [58] Children, 3-7 years 83 (25) > 9.7 ppb 86 92
Dupont 2003 [50] Adults 160 (66) > 16 ppb 49 90
Berkman 2005 [57] Adults 40 (47) > 7 ppb 82 89
Sivan 2009 [51] Children, 12-18 years 106 (70) > 19 ppb 86 89
Sachs-Olsen 2010 [52] Children, 10-12 years 60 (45) > 20.4 ppb 41 97
Pérez Tarazona 2011 [53] Children, 6-14 years 57 (40) > 19 ppb 91 87
Yao 2011 [54] Children, 5-18 years 70 (4.5) > 28 ppb 64 70
Cordeiro 2011 [55] Adults, Children 42 (30) > 27 ppb 78 92
Woo 2012 [56] Children, 8-16 years 167 (68) > 22 ppb 57 87
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even though they do not have asthma [65], but the me-
chanism is unclear.
Obesity is another confounding factor in the assessment
of FeNO levels. A consistent body of data now indicates
that asthma is closely related to obesity, and obese patients
with asthma usually have more severe symptoms than non-
obese asthmatics [66]. Indeed, obese asthma may be a
unique phenotype that is characterized by more severe
symptoms for a given degree of lung function impairment,
destabilization or lack of asthma control, worse quality of
life, lack of eosinophilic inflammation and a different
response to controller medication [67]. At any age, obesity
can adversely impact on lung function, and obesity duration
is a determinant of lower pulmonary function [68]. FeNO
levels have been extensively investigated in pediatric excess
adiposity [9,69]. Some pediatric studies showed that FeNO
is negatively associated with body mass index, waist-to-hip
ratio, and percent body fat [70], while others found no rela-
tionship between FeNO levels and adiposity measures
[69,71]. Furthermore, FeNO levels do not differ between
obese and normal weight subjects with asthma [9]. A pos-
sible explanation for this results might be a selection bias,
in particular overdiagnosis of asthma attributable to non
specific obesity-related respiratory symptoms among obese
children. Indeed, recent meta-analyses have pointed out
that some obese patients with “asthma” may have respira-
tory symptoms caused by obesity without objective physio-
logical criteria for asthma, or an exaggerated symptom
perception [72].
As far as the discrimination between children with
asthma and healthy subjects, FeNO measurement pro-
vides significantly higher diagnostic accuracy than lung
function tests [58,73], and has diagnostic value compar-
able to that of conventional bronchial challenge tests [57].
Several studies showed an inverse correlation between
FeNO levels and bronchial hyperreactivity tests in children
[58,70-76], and only one group did not confirm this find-
ing [77]. Nevertheless, elevated FeNO levels increase the
probability of exercise-induced bronchoconstriction inasthmatic school-age children [78]. These conflicting
results may be explained with the different methods used
to measure FeNO as well as with the heterogeneity of the
study populations, in particular regarding the presence of
atopy and the use of steroids.
Cut-points rather than reference values have been pro-
posed to interpret FeNO levels [33,34,72,79]. In children,
FENO values less than 20 ppb indicate that eosinophilic
inflammation is less likely, or that in patients presenting
with non specific respiratory symptoms alternative diag-
noses to asthma should be considered [79]. High FeNO
concentration (>35 ppb in children) strongly suggests
significant airway eosinophilia [79]. At high expiratory
flows, ranging from 200 to 280 mL/s, the negative and
positive predictive values for FeNO >25 ppb as predictor
of asthma rise to 80% and 100%, respectively [80]. None-
theless, intermediate FeNO levels (20-35 ppb in children)
indicate that cautious interpretation in the etiology of the
airway disorder is required.
An additional, novel, potential and attractive application
of FeNO in asthma is the “prediction” of asthma onset. In
the absence of symptoms, increased FeNO levels may re-
flect subclinical airway inflammation that may be predictive
of “early asthma”, especially in allergic subjects [81,82]. This
could be explained by an enhanced Th2 cytokine-driven
airway response in allergic individuals that may precede the
clinical presentation. Furthermore, in asymptomatic adoles-
cents, increased FeNO may predict the development of
rhinitis symptoms within a follow-up period of 4 years [83],
suggesting that FeNO may be a sensitive biomarker of the
“allergic march”. These findings have potential clinical and
therapeutic implications, also because studies in animal
models seem to show a possibility to block induction of
Th2 responses, thus preventing the development of future
asthma [84].
FeNO in the follow-up of bronchial asthma
The goal of asthma long-term treatment is to reduce in-
flammation for controlling symptoms. Treatment
options are usually guided by symptoms and lung
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airway inflammation. This is also shown by contrasting
results of studies on the relationship between FeNO
levels and both symptoms (including recent symptoms,
symptom frequency, symptom scores), symptom control,
or rescue ß2-agonist use [77,85-94] and pulmonary func-
tion test results [25,85-87,89,91,93-100].
Inhaled corticosteroids (ICS) are the first choice for
asthma maintenance treatment. Interestingly, inhaled or
systemic corticosteroid administration results in dose
dependent reductions of FeNO levels [27,100]. More-
over, in corticosteroid-naïve patients with suspected
asthma, the baseline FeNO value may predict an ICS re-
sponse in terms of improved lung function and reduced
airway reactivity [73]. Therefore, FeNO seems a suitable
biomarker for modifying ICS dose in order to obtain
better asthma control [101]. However, in children, daily
monitoring of FeNO at home [102], as well as measure-
ment of FeNO levels every 3 months for 1 year [103], or
5 times in 6 weeks [104] do not provide any advantage
in improving the symptom score. In adolescents and
adults, Szefler et al showed that the addition of FeNO
measurement as an indicator of asthma control resulted
in higher doses of ICS and long-acting β2 agonists than
did standard guideline-based treatment, and did not de-
termine improvements in asthma symptoms or lung
function [105]. A recent meta-analysis concluded that
the number of asthma exacerbations is not significantly
reduced in adults and children when ICS was tailored
based on FeNO [106].
These findings may be explained by the fact that
day-to-day variations of FeNO are common and do
not correlate with changes in symptom score [107].
Furthermore, some atopic asthmatic patients showed
a lack of FeNO responsiveness to ICS [108,109], or
may have increased FeNO levels despite high dose
ICS [110].
Another issue is whether the change in FeNO values
may be a better predictor than absolute levels. FeNO
levels quickly decrease in response to ICS and therefore
they may be useful to ascertain that ICS is regularly
taken. Finally, baseline FeNO seems a worse predictor of
asthma improvement than the change in FeNO after 80
days of ICS [111].
According to the Clinical Practice Guideline of the
American Thoracic Society (ATS) [79] it has been sug-
gested to consider as significant the increase in FeNO
greater than 20% for values over 50 ppb, or more than
10 ppb for values lower than 50 ppb from one visit to
the next. The second one recommends to use a reduc-
tion of at least 20% in FeNO for values over 50 ppb (or
more than 10 ppb for values lower than 50 ppb) as the
cut point to indicate as significant the response to anti-
inflammatory therapy.The results of two recent studies indicate new possible
clinical applications of FeNO measurement in pediatric
asthma. Pifferi et al assessed the value of spirometry and
FeNO measurements, alone or in combination, in mo-
dels developed by a machine learning approach for the
objective classification of asthma control [112]. The
combined use of spirometry parameters and FeNO levels
modeled by a soft computing learning approach applied
to spirometry could discriminate the level of asthma
control. Van der Valk et al found that FeNO measured
daily by a hand-held device started to increase approxi-
mately 10 days before moderate exacerbations occurred,
this suggesting that regular FeNO measurements in the
home setting could help to detect and even to prevent
the loss of asthma control [113]. Apart from ICS, other
established controller therapies, such as leukotriene
modifiers or anti-IgE therapy with omalizumab, have
been demonstrated to reduce FeNO in children, alone or
combined with ICS [114-117].
On the basis of the studies that have provided evi-
dence regarding the applications of NO measurements
in clinical practice, ATS recently indicated the rationale
for FeNO measurement in asthma, even in the pediatric
population [79], highlighting the following situations:
– Diagnosis of eosinophilic airway inflammation
– Support of asthma diagnosis when objective
evidence is needed
– Baseline evaluation and follow-up monitoring of
airway inflammation
– Assessment of potential response or failure to
respond to inhaled corticosteroids
– Evaluation of adherence to antiinflammatory
medications
– Guide for dose changes in antiinflammatory
medications
FeNO in viral bronchiolitis
Respiratory Syncytial Virus (RSV) manifests restricted tro-
pism for the respiratory epithelium stimulating an inflam-
matory response [118]. RSV increases NOS2 messenger
RNA, and upregulates NOS2 and its nitrite products in
lines and cultures of respiratory epithelial cells [119-121].
Despite in vitro and animal data demonstrated NO involve-
ment in bronchiolitis [120, 122], only few studies evaluated
FeNO levels in children with RSV bronchiolitis. Surpris-
ingly, FeNO appeared significantly lower in infants with
bronchiolitis than in healthy controls or in preschool chil-
dren with recurrent wheezing [123]. However, the same
study demonstrated that 3 months after the diagnosis of
RSV bronchiolitis, FeNO appeared significantly higher in
affected children than in normal subjects, suggesting that
low FeNO reflects the active suppression of NO production
occurring during the active infection, while the increased
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Future studies will hopefully provide more insights on
the relationship between viral infections and subsequent
chronic bronchial asthma.
FeNO in community acquired pneumonia
The scientific literature on FeNO modifications during
community acquired pneumonia (CAP) in children is
scarce. Since NO is part of the innate inflammatory re-
sponse, its levels are expected to rise in acute lung infec-
tion. Healthy children with an abnormally high FeNO had
significantly increased frequency of previous bronchitis or
pneumonia in the past year [124]. However, Carraro and
colleagues measured FeNO three times over a 1 month
period in the exhaled breath condensate obtained from
children with chest x-ray evidence of CAP, and found no
significant differences in FeNO levels either from children
with CAP compared to healthy controls, or from baseline
levels during the follow-up [125]. Different hypotheses
might explain this paradox. First, NO output from expira-
tory flows of 50 mL/s mainly derives from airway NO diffu-
sion, and therefore at higher flow rates, that sample from
the deeper parts of the lung, higher NO levels might be
found. Second, NO might also react rapidly with reactive
oxygen species, forming NO-metabolites. Unfortunately,
the above mentioned data do not allow to reach definitive
conclusions, and highlight the need for further studies on
the role of FeNO in children with CAP.
FeNO in bronchiectasis
Bronchiectasis is caused by, or associated with, many disor-
ders including congenital/genetic conditions, e.g. cystic
fibrosis (CF), primary immunodeficiency, primary ciliary
dyskinesia (PCD), Mounier-Kuhn syndrome, chronic
obstructive pulmonary disease, bronchiolitis obliterans,
sarcoidosis, autoimmune disorders, and acquired post-
infectious diseases [126-131]. High-resolution computed
tomography (HRCT) is the gold standard for the diagnosis
[128,132], even though radiation, magnetic resonance im-
aging has been proposed as an alternative radiation-free
technique, especially in children [133, 134].
Levels of inflammation in stable bronchiectasis seem
to correlate with a reduction of patient’s quality of life
[135]. Therefore, monitoring inflammation is of out-
standing relevance in the management of affected
patients, especially for preventing the disease progres-
sion. Since current markers of inflammation in the blood
and in the sputum are indirect, variable and invasive,
FeNO measurement may represent a useful way to as-
sess airway inflammation in patients with bronchiectasis.
Some studies found that FeNO levels from adults with
non-CF, non-PCD bronchiectasis are significantly higher
compared to controls [136-138], but others did not con-
firm this [80,139,140]. In children with bronchiectasisdue to CF or PCD, FeNO levels are abnormally low
compared to non CF- non PCD-patients or to controls,
but there are no significant differences between PCD
and CF [80,141-143].
NO measurement at different expiratory flow rates allows
to assess the contribution of NO from different parts of the
lung. A two-compartment model of pulmonary NO
exchange dynamics has been proposed to demonstrate rela-
tive contributions of bronchial (J) and peripheral (Calv)
airway NO to the final FeNO concentration [144]. In adults
with non CF- non PCD- bronchiectasis an increase in
CalvNO with normal JNO levels has been recently demon-
strated [136]. In children with CF-related bronchiectasis
results appear conflicting, with one study showing lower
JNO in CF than controls and no difference in CalvNO be-
tween groups [145], whereas other authors demonstrated
that children with CF had a significantly higher CalvNO,
but no significant difference in JNO compared to healthy
children [146]. On the other hand, in children with PCD,
very low levels of nasal NO are still a partially unexplained
feature, whereas FeNO levels show considerable overlap
with healthy subjects [80]. Paraskakis and colleagues found
that in children with PCD JNO was significantly reduced,
but CalvNO was normal compared with healthy controls
[147]. On the basis of these findings, authors speculate that
the normal CalvNO values militate against a generalized
disorder of NO metabolism in PCD children, and
hypothesize that NOS3 (endothelial) has normal function
in PCD, while the uncoupling of the contractile process of
the cilia from NOS2 (inducible) may result in failure of NO
production.
Notwithstanding the conflicting results between
affected children and adults, FeNO measurement could
represent a useful non invasive tool to monitor bronchial
inflammation over time.
FeNO in diffuse lung disease
The term diffuse lung disease (DLD) encompasses a he-
terogeneous group of chronic respiratory disorders charac-
terized by abnormal gas exchange and diffuse radiographic
and histopathologic abnormalities [148]. DLD is rare in
children, and diagnosis requires detailed history, complete
physical examination, lung imaging, pulmonary function
testing, bronchoalveolar lavage (BAL), and in most cases
an open lung biopsy to confirm the suspicion [148,149].
Several studies evaluated FeNO levels in adults with
DLD. In systemic sclerosis, FeNO concentrations are
lower in subjects with interstitial lung involvement than
in those without, whereas patients without pulmonary
disease have higher FeNO than healthy subjects [150].
Moreover, FeNO levels seem to be increased in subjects
with asbestosis [151], but not in pulmonary sarcoidosis
[152]. To the best of our knowledge, no studies ever
evaluated FeNO levels in children with DLD. This would
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tions, hopefully being useful in the evaluation of the pro-
gression of the disease, or of the response to treatment.
FeNO in bronchiolitis obliterans
Bronchiolitis obliterans (BO) is almost secondary to lung
transplantation in adults [153], while the most common
form in children is post-infectious BO [154]. FeNO
levels are increased in adult BO that occurs after lung
transplantation [155,156], and correlate with NOS2 ex-
pression in the bronchial epithelium and with the per-
centage of BAL neutrophils [157-161]. No pediatric
studies evaluating the role of FeNO in children with BO
after lung transplantation have been published. The
availability of a non-invasive biomarker that can identify
patients in whom more invasive diagnostic procedures
such as BAL or lung biopsies are justified (or can be
avoided) would be very helpful to improve the manage-
ment of children with BO.
Conclusions
NO seems to significantly influence a variety of physio-
logical and pathophysiological processes in the upper
and lower airways. FeNO measurement is easy to per-
form, and seems reproducible also in the preschool age.
The availability of hand-held devices will hopefully in-
crease its use in the pediatric practice. Combined with
symptoms registration and lung function measurements,
FeNO provides additional information that can be ap-
plied to support the diagnosis of asthma and to optimize
the management of affected children. Moreover, recent
studies suggest that FeNO is helpful in predicting both
onset and exacerbations of asthma. Since most studies
have been performed in adult populations, more re-
search is needed to confirm the usefulness of NO mea-
surement in the diagnosis and management of pediatric
chronic airway disorders different from asthma.
Abbreviations
NO: Nitric oxide; NOS: NO synthase; FeNO: Fractional exhaled nitric oxide;
ICS: Inhaled corticosteroids; RSV: Respiratory syncytial virus; CAP: Community
acquired pneumonia; CF: Cystic fibrosis, PCD, Primary ciliary dyskinesia;
HRCT: High-resolution computed tomography; DLD: Diffuse lung disease;
BAL: Bronchoalveolar lavage; BO: Bronchiolitis obliterans.
Competing interests
All authors declare that they have no significant competing financial,
professional or personal interests that might have influenced the
performance or presentation of the work described in this manuscript.
Authors’ contributions
AM has been involved in drafting the manuscript; CC has been involved in
revising the manuscript critically for important intellectual content; MV has
made substantial contributions to acquisition, analysis and interpretation of
data; CP has made substantial contributions to acquisition, analysis and
interpretation of data; SM has been involved in drafting the manuscript; MM
has been involved in drafting the manuscript; FSp has made substantial
contributions to acquisition, analysis and interpretation of data; FS has been
involved in drafting the manuscript, revising it critically for importantintellectual content and has given final approval of the version to be
published. All authors read and approved the final manuscript.
Author details
1Department of Pediatrics, Federico II University, Via Sergio Pansini, 5 80131,
Naples, Italy. 2Department of Pediatrics, University Hospital of Parma, Parma,
Italy.
Received: 11 October 2012 Accepted: 19 December 2012
Published: 31 December 2012
References
1. Moncada S, Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med
1993, 329:2002–2012.
2. Maniscalco M, Sofia M, Pelaia G: Nitric oxide in upper airways
inflammatory diseases. Inflamm Res 2007, 56:58–69.
3. Kharitonov SA, Barnes PJ: Exhaled markers of pulmonary disease.
Am J Respir Crit Care Med 2001, 163:1693–1722.
4. Lundberg JO, Farkas-Szallasi T, Weitzberg E, Rinder J, Lidholm J, Anggåard A,
Hökfelt T, Lundberg JM, Alving K: High nitric oxide production in human
paranasal sinuses. Nat Med 1995, 1:370–373.
5. American Thoracic Society; European Respiratory Society: ATS/ERS
recommendations for standardized procedures for the online and offline
measurement of exhaled lower respiratory nitric oxide and nasal nitric
oxide, 2005. Am J Respir Crit Care Med 2005, 171:912–930.
6. Baraldi E, Carraro S: Exhaled NO and breath condensate. Paediatr Respir Rev
2006, 7(Suppl 1):20–22.
7. Montella S, Alving K, Maniscalco M, Sofia M, De Stefano S, Raia V,
Santamaria F: Measurement of nasal nitric oxide by hand-held and
stationary devices. Eur J Clin Invest 2011, 41:1063–1070.
8. Santamaria F, De Stefano S, Montella S, Barbarano F, Iacotucci P, Ciccarelli R,
Sofia M, Maniscalco M: Nasal nitric oxide assessment in primary ciliary
dyskinesia using aspiration, exhalation, and humming. Med Sci Monit
2008, 14:80–85.
9. Santamaria F, Montella S, De Stefano S, Sperlì F, Barbarano F, Spadaro R,
Franzese A: Asthma, atopy, and airway inflammation in obese children.
J Allergy Clin Immunol 2007, 120:965–967.
10. Corradi M, Zinelli C, Caffarelli C: Exhaled breath biomarkers in asthmatic
children. Inflamm Allergy Drug Targets 2007, 6:150–159.
11. Baraldi E, de Jongste JC, European Respiratory Society/American Thoracic
Society (ERS/ATS) Task Force: Measurement of exhaled nitric oxide in
children, 2001. Eur Respir J 2002, 20:223–237.
12. Buchvald F, Bisgaard H: FeNO measured at fixed exhalation flow rate
during controlled tidal breathing in children from the age of 2 yr.
Am J Respir Crit Care Med 2001, 163:699–704.
13. Borrill Z, Clough D, Truman N, Morris J, Langley S, Singh D: A comparison
of exhaled nitric oxide measurements performed using three different
analysers. Respir Med 2006, 100:1392–1396.
14. Alving K, Janson C, Nordvall L: Performance of a new hand-held device for
exhaled nitric oxide measurement in adults and children. Respir Res 2006, 7:67.
15. Boot JD, de Ridder L, de Kam ML, Calderon C, Mascelli MA, Diamant Z:
Comparison of exhaled nitric oxide measurements between NIOX MINO
electrochemical and Ecomedics chemiluminescence analyzer. Respir Med
2008, 102:1667–1671.
16. Menzies D, Nair A, Lipworth BJ: Portable exhaled nitric oxide
measurement: Comparison with the "gold standard" technique.
Chest 2007, 131:410–414.
17. Korn S, Telke I, Kornmann O, Buhl R: Measurement of exhaled nitric oxide:
comparison of different analysers. Respirology 2010, 15:1203–1208.
18. Baraldi E, Azzolin NM, Cracco A, Zacchello F: Reference values of exhaled
nitric oxide for healthy children 6-15 years old. Pediatr Pulmonol 1999,
27:54–58.
19. Buchvald F, Baraldi E, Carraro S, Gaston B, De Jongste J, Pijnenburg MW,
Silkoff PE, Bisgaard H: Measurements of exhaled nitric oxide in healthy
subjects age 4 to 17 years. J Allergy Clin Immunol 2005, 115:1130–1136.
20. Kovesi T, Kulka R, Dales R: Exhaled nitric oxide concentration is affected
by age, height, and race in healthy 9- to 12-year-old children. Chest 2008,
133:169–175.
21. Wong GW, Liu EK, Leung TF, Yung E, Ko FW, Hui DS, Fok TF, Lai CK:
High levels and gender difference of exhaled nitric oxide in Chinese
schoolchildren. Clin Exp Allergy 2005, 35:889–893.
Manna et al. Italian Journal of Pediatrics 2012, 38:74 Page 7 of 10
http://www.ijponline.net/content/38/1/7422. Malmberg LP, Petäys T, Haahtela T, Laatikainen T, Jousilahti P, Vartiainen E,
Mäkelä MJ: Exhaled nitric oxide in healthy nonatopic school-age children:
determinants and height-adjusted reference values. Pediatr Pulmonol
2006, 41:635–642.
23. Yao TC, Lee WI, Ou LS, Chen LC, Yeh KW, Huang JL, PATCH Study Group:
Reference values of exhaled nitric oxide in healthy Asian children aged 5
to 18 years. Eur Respir J 2012, 39:378–384.
24. Dötsch J, Demirakça S, Terbrack HG, Hüls G, Rascher W, Kühl PG: Airway
nitric oxide in asthmatic children and patients with cystic fibrosis.
Eur Respir J 1996, 9:2537–2540.
25. Silvestri M, Spallarossa D, Frangova Yourukova V, Battistini E, Fregonese B,
Rossi GA: Orally exhaled nitric oxide levels are related to the degree of
blood eosinophilia in atopic children with mild-intermittent asthma.
Eur Respir J 1999, 13:321–326.
26. Franklin PJ, Taplin R, Stick SM: A community study of exhaled nitric oxide
in healthy children. Am J Respir Crit Care Med 1999, 159:69–73.
27. Latzin P, Beck J, Griese M: Exhaled nitric oxide in healthy children:
variability and a lack of correlation with atopy. Pediatr Allergy Immunol
2002, 13:37–46.
28. Jouaville LF, Annesi-Maesano I, Nguyen LT, Bocage AS, Bedu M, Caillaud D:
Interrelationships among asthma, atopy, rhinitis and exhaled nitric oxide in
a population-based sample of children. Clin Exp Allergy 2003, 33:1506–1511.
29. Grob NM, Dweik RA: Exhaled nitric oxide in asthma. From diagnosis, to
monitoring, to screening: are we there yet? Chest 2008, 133:837–839.
30. Olin AC, Bake B, Torén K: Fraction of exhaled nitric oxide at 50 mL/s:
reference values for adult lifelong never-smokers. Chest 2007,
131:1852–1856.
31. Travers J, Marsh S, Aldington S, Williams M, Shirtcliffe P, Pritchard A,
Weatherall M, Beasley R: Reference ranges for exhaled nitric oxide derived
from a random community survey of adults. Am J Respir Crit Care Med
2007, 176:238–242.
32. Taylor DR, Mandhane P, Greene JM, Hancox RJ, Filsell S, McLachlan CR,
Williamson AJ, Cowan JO, Smith AD, Sears MR: Factors affecting exhaled
nitric oxide measurements: the effect of sex. Respir Res 2007, 8:82.
33. Global Strategy for Asthma Management and Prevention. Global Initiative for
Asthma (GINA). http://www.ginasthma.org/.
34. British Thoracic Society Scottish Intercollegiate Guidelines Network: British
Guideline on the Management of Asthma. Thorax 2008, 63(Suppl 4):1–121.
35. Chedevergne F, Le Bourgeois M, de Blic J, Scheinmann P: The role of
inflammation in childhood asthma. Arch Dis Child 2000, 82(Suppl 2):6–9.
36. Caffarelli C, Calcinai E, Rinaldi L, Povesi Dascola C, Terracciano L, Corradi M:
Hydrogen peroxide in exhaled breath condensate in asthmatic children
during acute exacerbation and after treatment. Respiration 2012,
84:291–298.
37. Alving K, Weitzberg E, Lundberg JM: Increased amount of nitric oxide in
exhaled air of asthmatics. Eur Respir J 1993, 6:1368–1370.
38. Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R, Shinebourne EA,
Barnes PJ: Increased nitric oxide in exhaled air of asthmatic patients.
Lancet 1994, 343:133–135.
39. Hamid Q, Springall DR, Riveros-Moreno V, Chanez P, Howarth P, Redington A,
Bousquet J, Godard P, Holgate S, Polak JM: Induction of nitric oxide synthase
in asthma. Lancet 1993, 342:1510–1513.
40. Baraldi E, Azzolin NM, Zanconato S, Dario C, Zacchello F: Corticosteroids
decrease exhaled nitric oxide in children with acute asthma. J Pediatr
1997, 131:381–385.
41. Byrnes CA, Dinarevic S, Shinebourne EA, Barnes PJ, Bush A: Exhaled nitric
oxide measurements in normal and asthmatic children. Pediatr Pulmonol
1997, 24:312–318.
42. Lundberg JO, Nordvall SL, Weitzberg E, Kollberg H, Alving K: Exhaled nitric
oxide in paediatric asthma and cystic fibrosis. Arch Dis Child 1996,
75:323–326.
43. Warke TJ, Fitch PS, Brown V, Taylor R, Lyons JD, Ennis M, Shields MD:
Exhaled nitric oxide correlates with airway eosinophils in childhood
asthma. Thorax 2002, 57:383–387.
44. Payne DN, Adcock IM, Wilson NM, Oates T, Scallan M, Bush A: Relationship
between exhaled nitric oxide and mucosal eosinophilic inflammation in
children with difficult asthma, after treatment with oral prednisolone.
Am J Respir Crit Care Med 2001, 164:1376–1381.
45. Lim S, Jatakanon A, Meah S, Oates T, Chung KF, Barnes PJ: Relationship
between exhaled nitric oxide and mucosal eosinophilic inflammation in
mild to moderately severe asthma. Thorax 2000, 55:184–188.46. Silvestri M, Sabatini F, Sale R, Defilippi AC, Fregonese L, Battistini E, Biraghi MG,
Rossi GA: Correlations between exhaled nitric oxide levels, blood
eosinophilia, and airway obstruction reversibility in childhood asthma are
detectable only in atopic individuals. Pediatr Pulmonol 2003, 35:358–363.
47. Lex C, Ferreira F, Zacharasiewicz A, Nicholson AG, Haslam PL, Wilson NM,
Hansel TT, Payne DN, Bush A: Airway eosinophilia in children with severe
asthma: predictive values of noninvasive tests. Am J Respir Crit Care Med
2006, 174:1286–1291.
48. Wenzel SE: Asthma: defining of the persistent adult phenotypes.
Lancet 2006, 368:804–813.
49. Brussee JE, Smit HA, Kerkhof M, Koopman LP, Wijga AH, Postma DS,
Gerritsen J, Grobbee DE, Brunekreef B, de Jongste JC: Exhaled nitric oxide
in 4-year-old children: relationship with asthma and atopy. Eur Respir J
2005, 25:455–461.
50. Dupont LJ, Demedts MG, Verleden GM: Prospective evaluation of the
validity of exhaled nitric oxide for the diagnosis of asthma. Chest 2003,
123:751–756.
51. Sivan Y, Gadish T, Fireman E, Soferman R: The use of exhaled nitric oxide
in the diagnosis of asthma in school children. J Pediatr 2009, 155:211–216.
52. Sachs-Olsen C, Lødrup Carlsen KC, Mowinckel P, Håland G, Devulapalli CS,
Munthe-Kaas MC, Carlsen KH: Diagnostic value of exhaled nitric oxide in
childhood asthma and allergy. Pediatr Allergy Immunol 2010,
21(1 Pt 2):213–221.
53. Pérez Tarazona S, Martínez Camacho RM, Alfonso Diego J, Escolano Serrano S,
Talens Gandía J: Diagnostic value of exhaled nitric oxide measurement in
mild asthma. An Pediatr (Barc) 2011, 75:320–328.
54. Yao TC, Ou LS, Lee WI, Yeh KW, Chen LC, Huang JL, PATCH study group:
Exhaled nitric oxide discriminates children with and without allergic
sensitization in a population-based study. Clin Exp Allergy 2011,
41:556–564.
55. Cordeiro D, Rudolphus A, Snoey E, Braunstahl GJ: Utility of nitric oxide for
the diagnosis of asthma in an allergy clinic population. Allergy Asthma
Proc 2011, 32:119–126.
56. Woo SI, Lee JH, Kim H, Kang JW, Sun YH, Hahn YS: Utility of fractional
exhaled nitric oxide (F(E)NO) measurements in diagnosing asthma. Respir
Med 2012, 106:1103–1109.
57. Berkman N, Avital A, Breuer R, Bardach E, Springer C, Godfrey S: Exhaled
nitric oxide in the diagnosis of asthma: comparison with bronchial
provocation tests. Thorax 2005, 60:383–388.
58. Malmberg LP, Pelkonen AS, Haahtela T, Turpeinen M: Exhaled nitric oxide
rather than lung function distinguishes preschool children with probable
asthma. Thorax 2003, 58:494–499.
59. Frank TL, Adisesh A, Pickering AC, Morrison JF, Wright T, Francis H, Fletcher A,
Frank PI, Hannaford P: Relationship between exhaled nitric oxide and
childhood asthma. Am J Respir Crit Care Med 1998, 158:1032–1036.
60. Lúdvíksdóttir D, Janson C, Högman M, Hedenström H, Björnsson E, Boman G:
Exhaled nitric oxide and its relationship to airway responsiveness and
atopy in asthma. BHR-Study Group. Respir Med 1999, 93:552–556.
61. Gratziou C, Lignos M, Dassiou M, Roussos C: Influence of atopy on exhaled
nitric oxide in patients with stable asthma and rhinitis. Eur Respir J 1999,
14:897–901.
62. Silvestri M, Sabatini F, Spallarossa D, Fregonese L, Battistini E, Biraghi MG,
Rossi GA: Exhaled nitric oxide levels in non-allergic and allergic mono- or
polysensitised children with asthma. Thorax 2001, 56:857–862.
63. Linn WS, Rappaport EB, Berhane KT, Bastain TM, Avol EL, Gilliland FD:
Exhaled nitric oxide in a population-based study of southern California
schoolchildren. Respir Res 2009, 10:28.
64. Vahlkvist S, Sinding M, Skamstrup K, Bisgaard H: Daily home measurements
of exhaled nitric oxide in asthmatic children during natural birch pollen
exposure. J Allergy Clin Immunol 2006, 117:1272–1276.
65. Zinelli C, Caffarelli C, Strid J, Jaffe A, Atherton DJ: Measurement of nitric
oxide and 8-isoprostane in exhaled breath of children with atopic
eczema. Clin Exp Dermatol 2009, 34:607–612.
66. Tantisira KG, Weiss ST: Complex interactions in complex traits: obesity and
asthma. Thorax 2001, 56(Suppl 2):64–73.
67. Santamaria F, Montella S, Pietrobelli A: Obesity and pulmonary disease:
unanswered questions. Obes Rev 2012, 13:822–833.
68. Santamaria F, Montella S, Greco L, Valerio G, Franzese A, Maniscalco M,
Fiorentino G, Peroni D, Pietrobelli A, De Stefano S, Sperlì F, Boner AL:
Obesity duration is associated to pulmonary function impairment in
obese subjects. Obesity (Silver Spring) 2011, 19:1623–1628.
Manna et al. Italian Journal of Pediatrics 2012, 38:74 Page 8 of 10
http://www.ijponline.net/content/38/1/7469. Santamaria F, Montella S, De Stefano S, Sperlì F, Barbarano F, Valerio G:
Relationship between exhaled nitric oxide and body mass index in
children and adolescents. J Allergy Clin Immunol 2005, 116:1163–1164.
70. Berg CM, Thelle DS, Rosengren A, Lissner L, Torén K, Olin AC: Decreased
fraction of exhaled nitric oxide in obese subjects with asthma
symptoms: data from the population study INTERGENE/ADONIX.
Chest 2011, 139:1109–1116.
71. Leung TF, Li CY, Lam CW, Au CS, Yung E, Chan IH, Wong GW, Fok TF:
The relation between obesity and asthmatic airway inflammation.
Pediatr Allergy Immunol 2004, 15:344–350.
72. Peroni DG, Pietrobelli A, Boner AL: Asthma and obesity in childhood: on
the road ahead. Int J Obes (Lond) 2010, 34:599–605.
73. Smith AD, Cowan JO, Filsell S, McLachlan C, Monti-Sheehan G, Jackson P,
Taylor DR: Diagnosing asthma: comparisons between exhaled nitric
oxide measurements and conventional tests. Am J Respir Crit Care Med
2004, 169:473–478.
74. Ciprandi G, Tosca MA, Capasso M: Exhaled nitric oxide in children with
allergic rhinitis and/or asthma: a relationship with bronchial
hyperreactivity. J Asthma 2010, 47:1142–1147.
75. Steerenberg PA, Janssen NA, de Meer G, Fischer PH, Nierkens S, van Loveren H,
Opperhuizen A, Brunekreef B, van Amsterdam JG: Relationship between
exhaled NO, respiratory symptoms, lung function, bronchial
hyperresponsiveness, and blood eosinophilia in school children.
Thorax 2003, 58:242–245.
76. Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ: Correlation
between exhaled nitric oxide, sputum eosinophils, and methacholine
responsiveness in patients with mild asthma. Thorax 1998, 53:91–95.
77. Strunk RC, Szefler SJ, Phillips BR, Zeiger RS, Chinchilli VM, Larsen G,
Hodgdon K, Morgan W, Sorkness CA, Lemanske RF Jr, Childhood Asthma
Research and Education Network of the National Heart, Lung, and Blood
Institute: Relationship of exhaled nitric oxide to clinical and inflammatory
markers of persistent asthma in children. J Allergy Clin Immunol 2003,
112:883–892.
78. Grzelewski T, Grzelewska A, Majak P, Stelmach W, Kowalska A, Stelmach R,
Janas A, Stelmach I: Fractional exhaled nitric oxide (FeNO) may predict
exercise-induced bronchoconstriction (EIB) in schoolchildren with atopic
asthma. Nitric Oxide 2012, 27:82–87.
79. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, Olin AC,
Plummer AL, Taylor DR, American Thoracic Society Committee on
Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications:
An official ATS clinical practice guideline: interpretation of exhaled nitric
oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011,
184:602–615.
80. Narang I, Ersu R, Wilson NM, Bush A: Nitric oxide in chronic airway
inflammation in children: diagnostic use and pathophysiological
significance. Thorax 2002, 57:586–589.
81. Warke TJ, Mairs V, Fitch PS, McGovern V, Ennis M, Shields MD: Exhaled nitric
oxide in relation to the clinical features of childhood asthma.
J Asthma 2004, 41:751–757.
82. Bastain TM, Islam T, Berhane KT, McConnell RS, Rappaport EB, Salam MT,
Linn WS, Avol EL, Zhang Y, Gilliland FD: Exhaled nitric oxide, susceptibility and
new-onset asthma in the Children's Health Study. Eur Respir J 2011, 37:523–531.
83. Malinovschi A, Alving K, Kalm-Stephens P, Janson C, Nordvall L:
Increased exhaled nitric oxide predicts new-onset rhinitis and
persistent rhinitis in adolescents without allergic symptoms. Clin Exp
Allergy 2012, 42:433–440.
84. Siegle JS, Hansbro N, Dong C, Angkasekwinai P, Foster PS, Kumar RK:
Blocking induction of T helper type 2 responses prevents development of
disease in a model of childhood asthma. Clin Exp Immunol 2011, 165:19–28.
85. Franklin PJ, Turner SW, Le Souëf PN, Stick SM: Exhaled nitric oxide and
asthma: complex interactions between atopy, airway responsiveness,
and symptoms in a community population of children. Thorax 2003,
58:1048–1052.
86. Stirling RG, Kharitonov SA, Campbell D, Robinson DS, Durham SR, Chung KF,
Barnes PJ: Increase in exhaled nitric oxide levels in patients with difficult
asthma and correlation with symptoms and disease severity despite
treatment with oral and inhaled corticosteroids.Asthma and Allergy
Group. Thorax 1998, 53:1030–1034.
87. Artlich A, Busch T, Lewandowski K, Jonas S, Gortner L, Falke KJ: Childhood
asthma: exhaled nitric oxide in relation to clinical symptoms. Eur Respir J
1999, 13:1396–1401.88. Roberts G, Hurley C, Bush A, Lack G: Longitudinal study of grass pollen
exposure, symptoms, and exhaled nitric oxide in childhood seasonal
allergic asthma. Thorax 2004, 59:752–756.
89. Nordvall SL, Janson C, Kalm-Stephens P, Foucard T, Torén K, Alving K:
Exhaled nitric oxide in a population-based study of asthma and allergy
in schoolchildren. Allergy 2005, 60:469–475.
90. Stern G, de Jongste J, van der Valk R, Baraldi E, Carraro S, Thamrin C, Frey U:
Fluctuation phenotyping based on daily fraction of exhaled nitric oxide
values in asthmatic children. J Allergy Clin Immunol 2011, 128:293–300.
91. Debley JS, Stamey DC, Cochrane ES, Gama KL, Redding GJ: Exhaled nitric
oxide, lung function, and exacerbations in wheezy infants and toddlers.
J Allergy Clin Immunol 2010, 125:1228–1234.
92. Green RJ, Klein M, Becker P, Halkas A, Lewis H, Kitchin O, Moodley T,
Masekela R: Disagreement between common measures of asthma
control in children. Chest 2012, in press.
93. Waibel V, Ulmer H, Horak E: Assessing asthma control: symptom scores,
GINA levels of asthma control, lung function, and exhaled nitric oxide.
Pediatr Pulmonol 2012, 47:113–118.
94. Rosias PP, Dompeling E, Dentener MA, Pennings HJ, Hendriks HJ, Van Iersel MP,
Jöbsis Q: Childhood asthma: exhaled markers of airway inflammation,
asthma control score, and lung function tests. Pediatr Pulmonol 2004,
38:107–114.
95. Colon-Semidey AJ, Marshik P, Crowley M, Katz R, Kelly HW: Correlation
between reversibility of airway obstruction and exhaled nitric oxide
levels in children with stable bronchial asthma. Pediatr Pulmonol 2000,
30:385–392.
96. Hunt J, Gaston B: Airway nitrogen oxide measurements in asthma and
other pediatric respiratory diseases. J Pediatr 2000, 137:14–20.
97. Piacentini GL, Bodini A, Costella S, Suzuki Y, Zerman L, Peterson CG,
Boner AL: Exhaled nitric oxide, serum ECP and airway responsiveness in
mild asthmatic children. Eur Respir J 2000, 15:839–843.
98. del Giudice MM, Brunese FP, Piacentini GL, Pedullà M, Capristo C, Decimo F,
Capristo AF: Fractional exhaled nitric oxide (FENO), lung function and
airway hyperresponsiveness in naïve atopic asthmatic children.
J Asthma 2004, 41:759–765.
99. Zietkowski Z, Bodzenta-Lukaszyk A, Tomasiak MM, Szymanski W, Skiepko R:
Effect of ciclesonide and fluticasone on exhaled nitric oxide in patients
with mild allergic asthma. Respir Med 2006, 100:1651–1656.
100. van Rensen EL, Straathof KC, Veselic-Charvat MA, Zwinderman AH, Bel EH,
Sterk PJ: Effect of inhaled steroids on airway hyperresponsiveness,
sputum eosinophils, and exhaled nitric oxide levels in patients with
asthma. Thorax 1999, 54:403–408.
101. Taylor DR, Pijnenburg MW, Smith AD, De Jongste JC: Exhaled nitric oxide
measurements: clinical application and interpretation. Thorax 2006,
61:817–827.
102. de Jongste JC, Carraro S, Hop WC, CHARISM Study Group, Baraldi E: Daily
telemonitoring of exhaled nitric oxide and symptoms in the treatment
of childhood asthma. Am J Respir Crit Care Med 2009, 179:93–97.
103. Pijnenburg MW, Bakker EM, Hop WC, De Jongste JC: Titrating steroids on
exhaled nitric oxide in children with asthma: a randomized controlled
trial. Am J Respir Crit Care Med 2005, 172:831–836.
104. Fritsch M, Uxa S, Horak F Jr, Putschoegl B, Dehlink E, Szepfalusi Z,
Frischer T: Exhaled nitric oxide in the management of childhood
asthma: a prospective 6-months study. Pediatr Pulmonol 2006,
41:855–862.
105. Szefler SJ, Mitchell H, Sorkness CA, Gergen PJ, O'Connor GT, Morgan WJ,
Kattan M, Pongracic JA, Teach SJ, Bloomberg GR, Eggleston PA, Gruchalla RS,
Kercsmar CM, Liu AH, Wildfire JJ, Curry MD, Busse WW: Management of
asthma based on exhaled nitric oxide in addition to guideline-based
treatment for inner-city adolescents and young adults: a randomised
controlled trial. Lancet 2008, 372:1065–1072.
106. Petsky HL, Cates CJ, Lasserson TJ, Li AM, Turner C, Kynaston JA, Chang AB:
A systematic review and meta-analysis: tailoring asthma treatment on
eosinophilic markers (exhaled nitric oxide or sputum eosinophils).
Thorax 2012, 67:199–208.
107. Pijnenburg MW, Floor SE, Hop WC, De Jongste JC: Daily ambulatory
exhaled nitric oxide measurements in asthma. Pediatr Allergy Immunol
2006, 17:189–193.
108. Pijnenburg MW, Bakker EM, Lever S, Hop WC, De Jongste JC: High
fractional concentration of nitric oxide in exhaled air despite steroid
treatment in asthmatic children. Clin Exp Allergy 2005, 35:920–925.
Manna et al. Italian Journal of Pediatrics 2012, 38:74 Page 9 of 10
http://www.ijponline.net/content/38/1/74109. Gelb AF, Taylor CF, Shinar CM, Gutierrez CA, Zamel N: Effect of fluticasone
250 microg/salmeterol 50 microg and montelukast on exhaled nitric
oxide in asthmatic patients. Can Respir J 2008, 15:193–198.
110. Buchvald F, Eiberg H, Bisgaard H: Heterogeneity of FeNO response to
inhaled steroid in asthmatic children. Clin Exp Allergy 2003,
33:1735–1740.
111. Michils A, Baldassarre S, Van Muylem A: Exhaled nitric oxide and asthma
control: a longitudinal study in unselected patients. Eur Respir J 2008,
31:539–546.
112. Pifferi M, Bush A, Pioggia G, Di Cicco M, Chinellato I, Bodini A, Macchia P,
Boner AL: Monitoring asthma control in children with allergies by soft
computing of lung function and exhaled nitric oxide. Chest 2011,
139:319–327.
113. van der Valk RJ, Baraldi E, Stern G, Frey U, de Jongste JC: Daily exhaled
nitric oxide measurements and asthma exacerbations in children.
Allergy 2012, 67:265–271.
114. Bisgaard H, Loland L, Oj JA: NO in exhaled air of asthmatic children is
reduced by the leukotriene receptor antagonist montelukast. Am J Respir
Crit Care Med 1999, 160:1227–1231.
115. Ghiro L, Zanconato S, Rampon O, Piovan V, Pasquale MF, Baraldi E: Effect of
montelukast added to inhaled corticosteroids on fractional exhaled nitric
oxide in asthmatic children. Eur Respir J 2002, 20:630–634.
116. Straub DA, Minocchieri S, Moeller A, Hamacher J, Wildhaber JH: The effect
of montelukast on exhaled nitric oxide and lung function in asthmatic
children 2 to 5 years old. Chest 2005, 127:509–514.
117. Silkoff PE, Romero FA, Gupta N, Townley RG, Milgrom H: Exhaled nitric
oxide in children with asthma receiving Xolair (omalizumab), a
monoclonal anti-immunoglobulin E antibody. Pediatrics 2004,
113:308–312.
118. Hoffman SJ, Laham FR, Polack FP: Mechanisms of illness during respiratory
syncytial virus infection: the lungs, the virus and the immune response.
Microb Infect 2004, 6:767–772.
119. Stark JM, Khan AM, Chiappetta CL, Xue H, Alcorn JL, Colasurdo GN: Immune
and functional role of nitric oxide in a mouse model of respiratory
syncytial virus infection. J Infect Dis 2005, 191:387–395.
120. Song W, Liu G, Bosworth CA, Walker JR, Megaw GA, Lazrak A, Abraham E,
Sullender WM, Matalon S: Respiratory syncytial virus inhibits lung
epithelial Na+ channels by up-regulating inducible nitric-oxide synthase.
J Biol Chem 2009, 284:7294–7306.
121. Tsutsumi H, Takeuchi R, Ohsaki M, Seki K, Chiba S: Respiratory syncytial
virus infection of human respiratory epithelial cells enhances inducible
nitric oxide synthase gene expression. J Leukoc Biol 1999, 66:99–104.
122. Kao YJ, Piedra PA, Larsen GL, Colasurdo GN: Induction and regulation of
nitric oxide synthase in airway epithelial cells by respiratory syncytial
virus. Am J Respir Crit Care Med 2001, 163:532–539.
123. Gadish T, Soferman R, Merimovitch T, Fireman E, Sivan Y: Exhaled nitric
oxide in acute respiratory syncytial virus bronchiolitis. Arch Pediatr
Adolesc Med 2010, 164:727–731.
124. Kovesi T, Dales R: Exhaled nitric oxide and respiratory symptoms in a
community sample of school aged children. Pediatr Pulmonol 2008,
43:1198–1205.
125. Carraro S, Andreola B, Alinovi R, Corradi M, Freo L, Da Dalt L, Baraldi E:
Exhaled leukotriene B4 in children with community acquired
pneumonia. Pediatr Pulmonol 2008, 43:982–986.
126. Pasteur MC, Bilton D, Hill AT, British Thoracic Society Bronchiectasis non-CF
Guideline Group: British Thoracic Society guideline for non-CF
bronchiectasis. Thorax 2010, 65(1):1–58.
127. Santamaria F, Montella S, Tiddens HA, Guidi G, Casotti V, Maglione M, de
Jong PA: Structural and functional lung disease in primary ciliary
dyskinesia. Chest 2008, 134:351–357.
128. Santamaria F, Montella S, Pifferi M, Ragazzo V, De Stefano S, De Paulis N,
Maglione M, Boner AL: A descriptive study of non-cystic fibrosis
bronchiectasis in a pediatric population from central and southern Italy.
Respiration 2009, 77:160–165.
129. Patel IS, Vlahos I, Wilkinson TM, Lloyd-Owen SJ, Donaldson GC, Wilks M,
Reznek RH, Wedzicha JA: Bronchiectasis, exacerbation indices, and
inflammation in chronic obstructive pulmonary disease. Am J Respir Crit
Care Med 2004, 170:400–407.
130. Chang AB, Masel JP, Masters B: Post-infectious bronchiolitis obliterans:
clinical, radiological and pulmonary function sequelae. Pediatr Radiol
1998, 28:23–29.131. Chang AB, Bilton D: Exacerbations in cystic fibrosis: 4–Non-cystic fibrosis
bronchiectasis. Thorax 2008, 63:269–276.
132. Santamaria F, Montella S, Camera L, Palumbo C, Greco L, Boner AL:
Lung structure abnormalities, but normal lung function in pediatric
bronchiectasis. Chest 2006, 130:480–486.
133. Montella S, Santamaria F, Salvatore M, Pignata C, Maglione M, Iacotucci P,
Mollica C: Assessment of chest high-field magnetic resonance imaging in
children and young adults with non-cystic fibrosis chronic lung disease:
comparison to high-resolution computed tomography and correlation
with pulmonary function. Invest Radiol 2009, 44:532–538.
134. Montella S, Maglione M, Bruzzese D, Mollica C, Pignata C, Aloj G, Manna A,
Esposito A, Mirra V, Santamaria F: Magnetic resonance imaging is an
accurate and reliable method to evaluate non-cystic fibrosis paediatric
lung disease. Respirology 2012, 17:87–91.
135. Wilson CB, Jones PW, O'Leary CJ, Hansell DM, Cole PJ, Wilson R: Effect of
sputum bacteriology on the quality of life of patients with
bronchiectasis. Eur Respir J 1997, 10:1754–1760.
136. Shoemark A, Devaraj A, Meister M, Ozerovitch L, Hansell DM, Wilson R:
Elevated peripheral airway nitric oxide in bronchiectasis reflects disease
severity. Respir Med 2011, 105:885–891.
137. Kharitonov SA, Wells AU, O'Connor BJ, Cole PJ, Hansell DM, Logan-Sinclair RB,
Barnes PJ: Elevated levels of exhaled nitric oxide in bronchiectasis. Am J
Respir Crit Care Med 1995, 151:1889–1893.
138. Horváth I, Loukides S, Wodehouse T, Csiszér E, Cole PJ, Kharitonov SA,
Barnes PJ: Comparison of exhaled and nasal nitric oxide and exhaled
carbon monoxide levels in bronchiectatic patients with and without
primary ciliary dyskinesia. Thorax 2003, 58:68–72.
139. Ho LP, Innes JA, Greening AP: Exhaled nitric oxide is not elevated in the
inflammatory airways diseases of cystic fibrosis and bronchiectasis. Eur
Respir J 1998, 12:1290–1294.
140. Tsang KW, Leung R, Fung PC, Chan SL, Tipoe GL, Ooi GC, Lam WK: Exhaled
and sputum nitric oxide in bronchiectasis: correlation with clinical
parameters. Chest 2002, 121:88–94.
141. Zihlif N, Paraskakis E, Lex C, Van de Pohl LA, Bush A: Correlation between
cough frequency and airway inflammation in children with primary
ciliary dyskinesia. Pediatr Pulmonol 2005, 39:551–557.
142. Robroeks CM, Rosias PP, van Vliet D, Jöbsis Q, Yntema JB, Brackel HJ,
Damoiseaux JG, den Hartog GM, Wodzig WK, Dompeling E: Biomarkers in
exhaled breath condensate indicate presence and severity of cystic
fibrosis in children. Pediatr Allergy Immunol 2008, 19:652–659.
143. Grasemann H, Michler E, Wallot M, Ratjen F: Decreased concentration of
exhaled nitric oxide (NO) in patients with cystic fibrosis. Pediatr Pulmonol
1997, 24:173–177.
144. Tsoukias NM, George SC: A two-compartment model of pulmonary nitric
oxide exchange dynamics. J Appl Physiol 1998, 85:653–666.
145. Keen C, Gustafsson P, Lindblad A, Wennergren G, Olin AC: Low levels of
exhaled nitric oxide are associated with impaired lung function in cystic
fibrosis. Pediatr Pulmonol 2010, 45:241–248.
146. Suri R, Paraskakis E, Bush A: Alveolar, but not bronchial nitric oxide
production is elevated in cystic fibrosis. Pediatr Pulmonol 2007, 42:1215–1221.
147. Paraskakis E, Zihlif N, Bush A: Nitric oxide production in PCD: possible
evidence for differential nitric oxide synthase function. Pediatr Pulmonol
2007, 42:876–880.
148. Vece TJ, Fan LL: Diagnosis and management of diffuse lung disease in
children. Paediatr Respir Rev 2011, 12:238–242.
149. Doan ML, Guillerman RP, Dishop MK, Nogee LM, Langston C, Mallory GB,
Sockrider MM, Fan LL: Clinical, radiological and pathological features of
ABCA3 mutations in children. Thorax 2008, 63:366–373.
150. Malerba M, Radaeli A, Ragnoli B, Airo' P, Corradi M, Ponticiello A, Zambruni A,
Grassi V: Exhaled nitric oxide levels in systemic sclerosis with and without
pulmonary involvement. Chest 2007, 132:575–580.
151. Sandrini A, Johnson AR, Thomas PS, Yates DH: Fractional exhaled nitric
oxide concentration is increased in asbestosis and pleural plaques.
Respirology 2006, 11:325–329.
152. Wilsher ML, Fergusson W, Milne D, Wells AU: Exhaled nitric oxide in
sarcoidosis. Thorax 2005, 60:967–970.
153. Estenne M, Hertz MI: Bronchiolitis obliterans after human lung
transplantation. Am J Respir Crit Care Med 2002, 166:440–444.
154. Zhang L, Irion K, Kozakewich H, Reid L, Camargo JJ, da Silva Porto N,
Silva FA Ae: Clinical course of postinfectious bronchiolitis obliterans.
Pediatr Pulmonol 2000, 29:341–350.
Manna et al. Italian Journal of Pediatrics 2012, 38:74 Page 10 of 10
http://www.ijponline.net/content/38/1/74155. Fisher AJ, Gabbay E, Small T, Doig S, Dark JH, Corris PA: Cross sectional
study of exhaled nitric oxide levels following lung transplantation.
Thorax 1998, 53:454–458.
156. Verleden GM, Dupont L, Lamont J, Buyse B, Delcroix M, Van Raemdonck D,
Lerut T, Vanhaecke J, Demedts MG: Is there a role for measuring exhaled
nitric oxide in lung transplant recipients with chronic rejection?
J Heart Lung Transplant 1998, 17:231–232.
157. Neurohr C, Huppmann P, Leuschner S, von Wulffen W, Meis T, Leuchte H,
Ihle F, Zimmermann G, Baezner C, Hatz R, Winter H, Frey L, Ueberfuhr P,
Bittmann I, Behr J, Munich Lung Transplant Group: Usefulness of exhaled
nitric oxide to guide risk stratification for bronchiolitis obliterans
syndrome after lung transplantation. Am J Transplant 2011, 11:129–137.
158. Van Muylem A, Knoop C, Estenne M: Early detection of chronic pulmonary
allograft dysfunction by exhaled biomarkers. Am J Respir Crit Care Med
2007, 175:731–736.
159. Brugière O, Thabut G, Mal H, Marceau A, Dauriat G, Marrash-Chahla R,
Castier Y, Lesèche G, Colombat M, Fournier M: Exhaled NO may predict
the decline in lung function in bronchiolitis obliterans syndrome.
Eur Respir J 2005, 25:813–819.
160. Verleden GM, Dupont LJ, Van Raemdonck DE, Vanhaecke J, Leuven Lung
Transplant Group: Accuracy of exhaled nitric oxide measurements for the
diagnosis of bronchiolitis obliterans syndrome after lung transplantation.
Transplantation 2004, 78:730–733.
161. Gabbay E, Walters EH, Orsida B, Whitford H, Ward C, Kotsimbos TC, Snell GI,
Williams TJ: Post-lung transplant bronchiolitis obliterans syndrome (BOS)
is characterized by increased exhaled nitric oxide levels and epithelial
inducible nitric oxide synthase. Am J Respir Crit Care Med 2000,
162:2182–2187.
doi:10.1186/1824-7288-38-74
Cite this article as: Manna et al.: Clinical application of exhaled nitric
oxide measurement in pediatric lung diseases. Italian Journal of Pediatrics
2012 38:74.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
